These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23357307)

  • 1. Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake.
    Manca I; Mastinu A; Olimpieri F; Falzoi M; Sani M; Ruiu S; Loriga G; Volonterio A; Tambaro S; Bottazzi ME; Zanda M; Pinna GA; Lazzari P
    Eur J Med Chem; 2013 Apr; 62():256-69. PubMed ID: 23357307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
    Sharma MK; Murumkar PR; Kanhed AM; Giridhar R; Yadav MR
    Eur J Med Chem; 2014 May; 79():298-339. PubMed ID: 24747288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
    J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
    J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2'-yl pyrazole carboxamides.
    Lazzari P; Pau A; Tambaro S; Asproni B; Ruiu S; Pinna G; Mastinu A; Curzu MM; Reali R; Bottazzi ME; Pinna GA; Murineddu G
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):254-76. PubMed ID: 22931442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands.
    Murineddu G; Asproni B; Corona P; Piras S; Lazzari P; Ruiu S; Legnani L; Toma L; Pinna GA
    Molecules; 2019 Apr; 24(9):. PubMed ID: 31035548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands.
    Pinna G; Loriga G; Lazzari P; Ruiu S; Falzoi M; Frau S; Pau A; Murineddu G; Asproni B; Pinna GA
    Eur J Med Chem; 2014 Jul; 82():281-92. PubMed ID: 24922543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
    Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
    J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
    Silvestri R; Ligresti A; La Regina G; Piscitelli F; Gatti V; Lavecchia A; Brizzi A; Pasquini S; Allarà M; Fantini N; Carai MA; Bigogno C; Rozio MG; Sinisi R; Novellino E; Colombo G; Di Marzo V; Dondio G; Corelli F
    Eur J Med Chem; 2010 Dec; 45(12):5878-86. PubMed ID: 20943290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentacycle derivatives as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Lee SH; Ahn K; Lee M; Han HK; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6632-6. PubMed ID: 19850473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, hypoglycemic activity and molecular modeling studies of pyrazole-3-carbohydrazides designed by a CoMFA model.
    Hernández-Vázquez E; Aguayo-Ortiz R; Ramírez-Espinosa JJ; Estrada-Soto S; Hernández-Luis F
    Eur J Med Chem; 2013 Nov; 69():10-21. PubMed ID: 23995214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands.
    Piscitelli F; Ligresti A; La Regina G; Gatti V; Brizzi A; Pasquini S; Allarà M; Carai MA; Novellino E; Colombo G; Di Marzo V; Corelli F; Silvestri R
    Eur J Med Chem; 2011 Nov; 46(11):5641-53. PubMed ID: 21996466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
    Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
    J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse.
    Fride E; Braun H; Matan H; Steinberg S; Reggio PH; Seltzman HH
    Pediatr Res; 2007 Nov; 62(5):533-6. PubMed ID: 17805201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model.
    Srivastava BK; Joharapurkar A; Raval S; Patel JZ; Soni R; Raval P; Gite A; Goswami A; Sadhwani N; Gandhi N; Patel H; Mishra B; Solanki M; Pandey B; Jain MR; Patel PR
    J Med Chem; 2007 Nov; 50(24):5951-66. PubMed ID: 17979261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
    Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
    Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
    Janero DR; Makriyannis A
    Expert Opin Emerg Drugs; 2009 Mar; 14(1):43-65. PubMed ID: 19249987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.
    Hurst D; Umejiego U; Lynch D; Seltzman H; Hyatt S; Roche M; McAllister S; Fleischer D; Kapur A; Abood M; Shi S; Jones J; Lewis D; Reggio P
    J Med Chem; 2006 Oct; 49(20):5969-87. PubMed ID: 17004712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.